Analysts Predict FHLC Will Hit $78
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Should l Buy PBH?
Source: NASDAQ.COM
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.00 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 65.550
Low
71.00
Averages
77.00
High
88.00
Current: 65.550
Low
71.00
Averages
77.00
High
88.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prestige Consumer Healthcare Reports Q3 2026 Earnings with Strategic Insights
- Sales Performance Review: Prestige Consumer Healthcare reported Q3 sales of $283 million, slightly exceeding forecasts despite a 2.4% year-over-year decline, indicating resilience in its diversified customer base amidst macroeconomic challenges and positive order trends in growth channels.
- Profitability Analysis: The adjusted diluted EPS was $1.14, down from $1.22 in the prior year, primarily due to lower sales and increased general and administrative costs, reflecting challenges in cost control for the company.
- Cash Flow and Capital Allocation: Free cash flow for the first nine months reached $208.8 million, up 12.9% year-over-year, while the company repurchased over $150 million in shares, demonstrating a commitment to shareholder returns and flexible capital allocation strategies.
- Future Outlook: The company narrowed its fiscal 2026 sales outlook to approximately $1.1 billion, with anticipated adjusted diluted EPS of $4.54, as management remains optimistic about ongoing improvements in Clear Eyes supply, emphasizing execution and incremental enhancements in core product supply.
See More
Prestige (PBH) Q3 2026 Earnings Call Transcript
See More
Prestige Consumer Healthcare Q3 Earnings Miss Expectations
- Earnings Report Disappointment: Prestige Consumer Healthcare reported a Q3 non-GAAP EPS of $1.14, missing expectations by $0.02, indicating pressure on profitability that could affect investor confidence.
- Revenue Decline: Q3 revenue was $283.4 million, down 2.4% year-over-year and missing market expectations by $3.12 million, reflecting challenges in the competitive landscape.
- Fiscal 2026 Outlook Adjustment: The company revised its FY26 revenue outlook to between $1.1 billion and $1.115 billion, indicating a cautious stance on future growth with an anticipated organic revenue decline of approximately 3%.
- Stable Cash Flow: Despite challenges, the company expects free cash flow to remain at $245 million or more, demonstrating robust cash management that may support future investments.
See More
2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts
Market Concerns: Investors are increasingly worried about high valuations, index concentration, circular finance, persistent inflation, and rising government debt.
Geopolitical Developments: A significant geopolitical event occurred on January 3, with the capture of Venezuelan President Nicolás Maduro and his wife by U.S. troops, adding to market uncertainties.
See More
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
See More
Premium Brands Acquires Stampede for $662.5 Million
- Acquisition Agreement: Premium Brands has entered into a definitive agreement to acquire Stampede Culinary Partners for approximately $662.5 million, consisting of $512.5 million in cash and $150 million in common shares, which is expected to significantly enhance its position in the U.S. foodservice market.
- Market Expansion: This acquisition will strengthen Premium Brands' presence in the U.S. foodservice channel, particularly as its current strategies are primarily focused on retail and club store channels, thereby driving overall company growth.
- Production Capability Enhancement: By acquiring Stampede, Premium Brands will gain sous vide cooking capabilities, enhancing its production capacity and is expected to realize cost and growth synergies, further boosting its competitive edge in the market.
- Financial Impact: The acquisition is anticipated to be immediately accretive to adjusted earnings per share, delivering mid-single digit percentage accretion in the first year, with a long-term goal of reducing the total funded debt to adjusted EBITDA ratio to 3.0:1 or lower by 2027.
See More
Prestige Consumer Healthcare Reports Q3 2026 Earnings with Strategic Insights
- Sales Performance Review: Prestige Consumer Healthcare reported Q3 sales of $283 million, slightly exceeding forecasts despite a 2.4% year-over-year decline, indicating resilience in its diversified customer base amidst macroeconomic challenges and positive order trends in growth channels.
- Profitability Analysis: The adjusted diluted EPS was $1.14, down from $1.22 in the prior year, primarily due to lower sales and increased general and administrative costs, reflecting challenges in cost control for the company.
- Cash Flow and Capital Allocation: Free cash flow for the first nine months reached $208.8 million, up 12.9% year-over-year, while the company repurchased over $150 million in shares, demonstrating a commitment to shareholder returns and flexible capital allocation strategies.
- Future Outlook: The company narrowed its fiscal 2026 sales outlook to approximately $1.1 billion, with anticipated adjusted diluted EPS of $4.54, as management remains optimistic about ongoing improvements in Clear Eyes supply, emphasizing execution and incremental enhancements in core product supply.
See More
Prestige (PBH) Q3 2026 Earnings Call Transcript
See More
Prestige Consumer Healthcare Q3 Earnings Miss Expectations
- Earnings Report Disappointment: Prestige Consumer Healthcare reported a Q3 non-GAAP EPS of $1.14, missing expectations by $0.02, indicating pressure on profitability that could affect investor confidence.
- Revenue Decline: Q3 revenue was $283.4 million, down 2.4% year-over-year and missing market expectations by $3.12 million, reflecting challenges in the competitive landscape.
- Fiscal 2026 Outlook Adjustment: The company revised its FY26 revenue outlook to between $1.1 billion and $1.115 billion, indicating a cautious stance on future growth with an anticipated organic revenue decline of approximately 3%.
- Stable Cash Flow: Despite challenges, the company expects free cash flow to remain at $245 million or more, demonstrating robust cash management that may support future investments.
See More
2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts
Market Concerns: Investors are increasingly worried about high valuations, index concentration, circular finance, persistent inflation, and rising government debt.
Geopolitical Developments: A significant geopolitical event occurred on January 3, with the capture of Venezuelan President Nicolás Maduro and his wife by U.S. troops, adding to market uncertainties.
See More
Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line
- E-Commerce Growth: Prestige Consumer reported double-digit consumption growth in e-commerce channels, with online sales representing up to 20% of total sales in fiscal 2025, reflecting the success of its digital strategies and enhancing market competitiveness.
- Acquisition Fuels Growth: The company announced the acquisition of Pillar5 Pharma, expected to close in Q3 of fiscal 2026, which will enhance supply capabilities in the eye care category, securing near-term supply and expanding long-term production capacity, thereby diversifying its product portfolio.
- Stable Solvency: As of the end of Q2 fiscal 2026, Prestige Consumer reported no short-term debt and cash equivalents of $119 million, indicating a robust financial position that helps mitigate risks from economic fluctuations.
- Cost Pressure Challenges: Despite facing approximately $5 million in tariff costs and supply chain disruptions, Prestige Consumer is proactively implementing cost-saving measures and tactical pricing strategies to offset these impacts, ensuring sustained profitability.
See More
Premium Brands Acquires Stampede for $662.5 Million
- Acquisition Agreement: Premium Brands has entered into a definitive agreement to acquire Stampede Culinary Partners for approximately $662.5 million, consisting of $512.5 million in cash and $150 million in common shares, which is expected to significantly enhance its position in the U.S. foodservice market.
- Market Expansion: This acquisition will strengthen Premium Brands' presence in the U.S. foodservice channel, particularly as its current strategies are primarily focused on retail and club store channels, thereby driving overall company growth.
- Production Capability Enhancement: By acquiring Stampede, Premium Brands will gain sous vide cooking capabilities, enhancing its production capacity and is expected to realize cost and growth synergies, further boosting its competitive edge in the market.
- Financial Impact: The acquisition is anticipated to be immediately accretive to adjusted earnings per share, delivering mid-single digit percentage accretion in the first year, with a long-term goal of reducing the total funded debt to adjusted EBITDA ratio to 3.0:1 or lower by 2027.
See More
